Clinical Trial

PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A phase 1, open-label, non-randomized study enrolling pediatric and young adult patients with relapsed or refractory CD33+ leukemia with and without prior history of allogeneic hematopoietic cell transplantation, to examine the safety and feasibility of administering an autologous T cell product that has been genetically modified to express a Dimerizing Agent Regulated Immunoreceptor Complex (DARIC).
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-10-25; most recent amendment 2025-12-16.
Status change: Not Yet Recruiting → Recruiting 2021-12-08
Trial Details
NCT Number NCT05105152
Lead Sponsor Seattle Children's Hospital
Collaborators: Regeneron Pharmaceuticals
Conditions Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
Enrollment 18 participants
Start Date 2021-11-29
Primary Completion 2028-02-28 (estimated)
Study Completion 2041-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-23